CD33 and neoplasm: Since former studies have found SIGLEC1 (CD169), SIGLEC2 (CD22), SIGLEC3 (CD33), SIGLEC7, SIGLEC9, and SIGLEC15 expressed by immune cell populations could be manipulated by tumor cells to escape immune surveillance, we focused on the five SIGLEC family members.